Decision Resources, Inc., announces the publication of Cytokine and Anticytokine Therapies in Immune and Inflammatory Diseases. Research indicates that cytokines-a group of intercellular regulatory proteins-are of paramount importance in the pathogenesis of numerous disorders. The successful use of two tumor necrosis factor-alpha (TNF-alpha) inhibitors, etanercept (Immunex's Enbrel) and infliximab (Centocor/Johnson & Johnson's Remicade), in clinical trials of rheumatoid arthritis (RA) and Crohn's disease provided the first convincing evidence of anticytokine therapy's potential in humans. Subsequently, pharmaceutical and biotechnology companies have invested substantial resources in the race to identify and target different cytokines for the treatment of various inflammatory diseases.


Cytokine-based therapies are rapidly entering mainstream clinical practice and are poised for explosive growth during our 1999-2009 forecast period. In the major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), we predict that sales of cytokine-based drugs for RA, asthma, IBD, and organ transplantation will grow at an annual pace of 14.5% through 2009 for a total value of $4.3 billion, excluding sales of therapies targeting TNF-alpha. A host of factors will drive this growth:

  -- Amgen's anakinra, a recombinant interleukin (IL)-1 receptor antagonist,      may prove effective in suppressing inflammation and in delaying disease      progression in RA. Patients refractory to treatment with TNF-alpha      inhibitors may receive this therapy alone or in combination with anti-      TNF therapy. Anakinra is preregistered in the United States and Europe      for the treatment of RA and is in Phase II clinical trials for IBD.   -- Immunex's Nuvance, a soluble IL-4 receptor, should continue to show      efficacy and prove to be safe in clinical trials in asthma patients. We      expect this drug to reach the U.S. market by 2004.   -- Other, more speculative factors contributing to market growth may      include the demonstration of protective effects from recombinant human      IL-11 (Genetics Institute's Neumega) for the treatment of IBD and the      approval of Schering-Plough's Tenovil (IL-10) for the treatment of RA      and IBD.  

Cytokine and Anticytokine Therapies in Immune and Inflammatory Diseases is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years.

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or (e-mail).


AP Archive:

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,

Arrhythmias Represent an Area of Untapped Potential in Cardiovascular Drug Development, According to a New Decision Resources Study

View Now